Search

Krystal Biotech Inc

Closed

SectorHealthcare

356 -1.02

Overview

Share price change

24h

Current

Min

351.1

Max

362.86

Key metrics

By Trading Economics

Income

-1.2M

55M

Sales

2.9M

119M

P/E

Sector Avg

43.421

57.366

EPS

1.79

Profit margin

45.938

Employees

295

EBITDA

2.9M

66M

Recommendations

By TipRanks

Recommendations

Strong Buy

12 Months Forecast

+13.05% upside

Dividends

By Acuity

Next Earnings

2 lis 2026

Market Stats

By TradingEconomics

Market Cap

-257M

10B

Previous open

357.02

Previous close

356

News Sentiment

By Acuity

14%

86%

26 / 340 Ranking in Healthcare

Krystal Biotech Inc Chart

Wyniki osiągnięte w przeszłości nie są gwarantem przyszłych wyników.

Related News

25 sie 2026, 20:07 UTC

Krystal Biotech Inc shares are higher today, benefiting from easing Treasury yields and strong momentum, despite no specific company news driving the move.

24 sie 2026, 19:16 UTC

Krystal Biotech Inc's shares are lower today, continuing a decline since Friday. Market focus remains on upcoming economic events amid inflation concerns.

21 sie 2026, 21:01 UTC

Krystal Biotech shares are lower in after-market trading, reflecting a modest decline since Friday's close amid limited price fluctuations.

20 sie 2026, 21:01 UTC

Krystal Biotech Inc shares are higher in after-market trading, maintaining a position above their 20-day moving average without any specific news to explain the rise.

19 sie 2026, 20:02 UTC

Correlated Moves

Shares rise amid positive momentum in biotechnology sector.

14 sie 2026, 19:46 UTC

News

RBC Capital initiated coverage on Krystal Biotech with an Outperform rating and a $400 price target, boosting shares higher since Thursday's close.

13 sie 2026, 19:46 UTC

Correlated Moves

Krystal Biotech Inc shares are lower, reflecting a broader decline in the biotechnology sector and trading below their 20-day moving average.

12 sie 2026, 20:52 UTC

Krystal Biotech Inc shares declined during after-market hours, trading near the lower end of its one-month range and below its 20-day moving average.

11 sie 2026, 21:01 UTC

Krystal Biotech Inc. shares rose in after-market trading, reaching a high of 1.23% above Tuesday's close, despite remaining below its 20-day moving average.

7 sie 2026, 19:26 UTC

Krystal Biotech Inc shares are higher during Friday's session, reflecting a gain since Thursday's close. No specific news was identified to explain the movement.

6 sie 2026, 19:26 UTC

Shares of Krystal Biotech Inc. are lower today, trading near the lower end of their one-month range and below the 20-day moving average.

5 sie 2026, 19:52 UTC

Krystal Biotech Inc shares are lower today, breaking a trend of higher closes. Broader market sentiment is cautious following ADP's weak employment report.

4 sie 2026, 20:04 UTC

News

Citigroup raised its price target on Krystal Biotech to $386, contributing to upward movement in shares despite earlier session pullbacks.

3 sie 2026, 23:06 UTC

Krystal Biotech Inc shares are higher in after-market hours, recovering from an earlier dip. Broader market sentiment improved following stronger-than-expected economic data.

31 lip 2026, 23:06 UTC

Krystal Biotech Inc is trading lower in after-market hours amid volatility, with no specific news identified to explain the movement.

30 lip 2026, 19:39 UTC

Krystal Biotech Inc shares are higher today, maintaining gains since Wednesday's close. The stock remains above its 20-day moving average despite a slight pullback.

29 lip 2026, 20:04 UTC

Krystal Biotech shares are lower amid a broader market decline, influenced by significant drops in major U.S. stocks ahead of the Federal Reserve's announcement.

28 lip 2026, 20:03 UTC

Event
Social Media

Krystal Biotech Inc. shares rise amid strong Biotechnology sector gains and positive social media discussions, with Q2 FY2026 earnings expected on August 3.

27 lip 2026, 22:02 UTC

Social Media

Shares of Krystal Biotech are lower in after-market hours, despite discussions of potential catalysts and an upcoming earnings report on August 3.

24 lip 2026, 19:11 UTC

Krystal Biotech Inc shares are higher today, despite broader market weakness. The stock has seen increased trading activity since Thursday's close.

23 lip 2026, 10:01 UTC

Krystal Biotech Inc shares are higher in pre-market hours, following a slight after-market increase on Wednesday. No specific news was identified for this movement.

22 lip 2026, 19:26 UTC

Krystal Biotech Inc shares are lower today amid a broader market decline, with no specific company news identified to explain the movement.

21 lip 2026, 18:36 UTC

News
Social Media

Krystal Biotech Inc shares are lower today amid trading volatility, despite a planned inclusion in the S&P MidCap 400 on July 24.

20 lip 2026, 21:21 UTC

News

Krystal Biotech Inc. will replace Taylor Morrison in the S&P MidCap 400 on July 24, 2026. The stock is lower in after-hours trading.

Peer Comparison

Price change

Krystal Biotech Inc Forecast

Price Target

By TipRanks

13.05% upside

12 Months Forecast

Average 402.67 USD  13.05%

High 474 USD

Low 361 USD

Based on 8 Wall Street analysts offering 12 month price targets forKrystal Biotech Inc - Dist in the last 3 months.

Rating Consensus

By TipRanks

Strong Buy

8 ratings

7

Buy

1

Hold

0

Sell

Sentiment

By Acuity

26 / 340 Ranking in Healthcare

News Sentiment

Very Strong Bullish Evidence

Volatility

Below average

News Volume (RCV)

Above average

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

$

About Krystal Biotech Inc

Krystal Biotech, Inc., a commercial-stage biotechnology company, discovers, develops, and commercializes genetic medicines for patients with rare diseases in the United States. It commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB). The company also develops KB105, which is in Phase 1/2 clinical trials for treating patients with deficient autosomal recessive congenital ichthyosis; KB104 for treating netherton syndrome; KB407 that is in Phase 1 clinical trials for treating cystic fibrosis; KB707 that is in Phase 1 clinical trials for the treatment of anti-PD-1 relapsed/refractory; KB408, which is in Phase 1 clinical trials for treating Alpha-1 antitrypsin deficiency; and KB301 that is in Phase 2 clinical trials for treating aesthetic skin conditions, as well as in open label study with ophthalmic B-VEC for treating for ocular complications of deb. Krystal Biotech, Inc. was founded in 2016 and is headquartered in Pittsburgh, Pennsylvania.
help-icon Live chat